RxDoctor Payments Data

Jessica Mastbergen, NP

Adult Health · Traverse City, MINPI 1023501699

Payments from drug & device makers

$1,039in general payments, 2019–2025

Across 46 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$196
  • Novo Nordisk$152
  • Amgen$66
  • GSK$56
  • Lilly USA, LLC$55
  • Boehringer Ingelheim$52
  • plus $463 from 15 others

What the payments were for

  • Food & beverage$98995%
  • Other$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,039 in reported general payments places this provider in the 70th percentile of 527 adult health providers in Michigan.

See all adult health providers in Michigan

Medicare billing

Part B allowed, 2024
$48,952
Medicare patients
135
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide220$279,752
JardianceEmpagliflozin137$176,231
TrulicityDulaglutide82$152,251
OzempicSemaglutide117$142,749
Humulin R U-500 KwikpenInsulin Regular, Human21$47,586
Tresiba Flextouch U-100Insulin Degludec45$39,891
FarxigaDapagliflozin Propanediol40$39,042
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$35,780
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$25,344
Tresiba Flextouch U-200Insulin Degludec16$19,587
JanuviaSitagliptin Phosphate19$18,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog96$17,258
Humalog Kwikpen U-100Insulin Lispro45$15,379
Xultophy 100-3.6Insulin Degludec/Liraglutide13$14,531
NovologInsulin Aspart32$11,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$55$444,518374 claims
Boehringer IngelheimJardiance$52$176,231137 claims
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$152$168,639162 claims
AstraZenecaFarxiga$13$39,04240 claims
MerckJanuvia$30$18,92619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 527 adult health providers in Michigan.

Other adult health in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →